Regeneron Achieves Phase 2 COURAGE Trial Milestone Confirming Trevogrumab Preserves Muscle Mass During GLP-1 Weight Loss

Regeneron Pharmaceuticals has moved trevogrumab closer to combination-therapy development after Phase 2 COURAGE trial data confirmed the anti-myostatin biologic preserved lean mass and muscle volume during semaglutide-induced weight loss, a finding with direct implications for manufacturers preparing to scale co-developed biologic and small-molecule regimens.

The trial evaluated trevogrumab across two independent dose portions over 52 weeks in adults with obesity (BMI ≥30 kg/m²). In the lower-dose portion, trevogrumab 75 mg combined with semaglutide 2.4 mg achieved 50.7% lean mass preservation at 26 weeks and 42.5% at 52 weeks relative to placebo plus semaglutide, as measured by DXA. A pre-specified MRI substudy reinforced those findings: lower-dose trevogrumab preserved approximately 70% of thigh muscle volume that would otherwise have been lost with semaglutide alone, with the 25 mg arm showing 71.8% preservation at 52 weeks.

A pre-specified subgroup analysis identified patients meeting the low lean mass definition for sarcopenia as experiencing disproportionate lean mass loss on semaglutide monotherapy, and correspondingly greater preservation benefit with trevogrumab. The results were presented at the European Association for the Study of Diabetes (EASD) Annual Meeting and are in press with The Lancet.

For QA directors and process development teams, the pipeline consequence is concrete: Regeneron has announced plans to initiate a Phase 2 trial evaluating trevogrumab in combination with GLP-1 receptor agonist-based therapies in older adults with obesity and decreased muscle mass or strength. Co-developing a monoclonal antibody alongside a GLP-1 agonist introduces compounded manufacturing complexity, separate upstream bioprocesses, distinct formulation requirements, and parallel analytical method validation packages that must satisfy 21 CFR Part 211 and ICH Q10 quality system expectations before any combination regimen reaches late-stage scale-up.

CDMOs and in-house manufacturers already managing GLP-1 capacity constraints will need to assess whether existing fill-finish infrastructure and cold-chain logistics can accommodate a concurrent biologic program without compromising sterility assurance or batch release timelines. The greatest lean mass loss in COURAGE occurred during the first six months of treatment, the period of most rapid weight loss, which may inform dosing schedules and, by extension, the production cadence required to support combination therapy supply.

The next measurable checkpoint is the initiation of the planned Phase 2 combination trial in older adults, where primary endpoint design and the regulatory submission strategy for a co-administered biologic-GLP-1 regimen will define the manufacturing development timeline.

Source: Regeneron Pharmaceuticals via GlobeNewswire, 1 October 2026. Results presented at the EASD Annual Meeting Scientific Symposium; manuscript in press at The Lancet.